Neuland Laboratories Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/mobn1y0x3atbt7dzytxcnoce.pdf

Key Takeaways


The Quarter: Lumpy by Design

Saharsh Davuluri: "This quarter's performance has been poor, especially when compared with what we've been doing over the last several quarters. But as I mentioned earlier, it does reflect the lumpy volatile nature of our business."

CMS: The Engine Taking Share


Biosecure Act: Rhetoric vs. Reality

Saharsh Davuluri: "We are in touch with our customers. We're engaging with them, finding out their preferences, how many projects are being outsourced, how many are going to China, how many come to India so that we keep our expectations, our projections and the related capital expenditure much closer to reality rather than get carried away by all the rhetoric that's happening in the market."

Capabilities & Competitive Positioning

Sucheth Davuluri: "The way we see at least Neuland strategy play out in the future is that we want to focus more and more on technologies, which are challenging that will continue to differentiate Neuland that will help us continue to focus on the quality of business rather than the quantity of business."

Growth Roadmap: Near, Medium & Long Term

Saharsh Davuluri: "I think it will be interesting to see how things play out, but we honestly believe that ultimately, the business is going to follow the economics of it. I think any kind of policies that will constrict basic economics are not going to be sustainable."

Margins & Mix


Guidance & Commitments

CommitmentSpecificsTimeline
FY25 revenueRelatively flat versus prior expectation of moderate growthFY25
FY26 growthBusiness to regain momentum with high growth, driven by new facilities and CMS commercial launchesFY26
Unit 3 production blockComplete construction by FY25; commence commercial productionFY26
Difelikefalin DMF filingFile the DMFNext year (FY26)
Tirzepatide DMF filingFile the DMFYear after next (FY27)
CMS revenue shareCross 50% shareNext couple of years

Key Metrics

MetricQ2 FY25
Total income₹315.2 cr, vs ₹420.8 cr in Q2 FY24
EBITDA₹65.7 cr, margin 20.8% vs ₹140.3 cr in Q2 FY24
Gross margin56.3%, vs 59.8% in Q2 FY24
Profit after tax₹32 cr, vs ₹89.1 cr in Q2 FY24
EPS₹24.9 per share
H1FY25 revenue₹759.6 cr, degrowth of 3.3% vs H1FY24
H1FY25 EBITDA₹194.3 cr, vs ₹239.6 cr in H1FY24
FY25 revenue outlookFlat vs FY24, revised from moderate growth
CMS revenues₹132 cr, driven by commercial segment molecules
CMS commercial APIsIncreased by 1, following FDA approval of an NCE API
Working capital112 days to sales
Free cash flow (H1FY25)₹45.8 cr
Net debtNegative ₹94.3 cr
Capital spend (H1FY25)₹103.5 cr, on facility upgradation
R&D scientist headcount~360, unchanged over last 2 years